Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax Statement on Proof of COVID-19 Vaccine Requirements for PREVENT-19 Clinical Trial Participants in the U.S.
- Statement
- COVID-19
Sep 17, 2021
Novavax Statement on Takeda Agreement to Provide 150 Million Doses of NVX-CoV2373 to the Government of Japan
- Statement
- COVID-19
Sep 10, 2021
Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants: Updated June 30, 2021
- Statement
- COVID-19
Jun 30, 2021
Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre
- Statement
- COVID-19
Jun 22, 2021
Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants in the United Kingdom
- Statement
- COVID-19
May 22, 2021
Complete Trial Results Manuscript of Novavax COVID-19 Investigational Vaccine Posted to Preprint Server medRxiv
- Statement
- COVID-19
May 21, 2021
Novavax Statement on Participation in Mix-and-Match COVID-19 Vaccine Booster Trial in the United Kingdom
- Statement
- COVID-19
May 21, 2021
Novavax Statement on Updated PREVENT-19 Trial Protocol
- Statement
- COVID-19
May 10, 2021
Novavax Statement on Ministry of Health, Labour and Welfare’s Announcement Regarding Procurement from Takeda of NVX-CoV2373 for Japan
- Statement
- COVID-19
May 7, 2021
Novavax Statement in Opposition to the WTO TRIPS Waiver
- Statement
- COVID-19
May 7, 2021

Show per page